Esperion Therapeutics
ESPR
C$2.02
Share price
-7.55%
Change (1 day)
-37.81%
Change (1 year)
Categories
Esperion Therapeutics (ESPR) - Cash on Hand
Cash on Hand as of March 2025 : C$0.15 Billion
According to Esperion Therapeutics's latest financial reports the company has C$0.15 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Esperion Therapeutics - Cash on Hand chart (from 2000 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | C$0.20 B | 90.42% |
| 2023-12-31 | C$0.10 B | -51.82% |
| 2022-12-31 | C$0.22 B | -31.49% |
| 2021-12-31 | C$0.33 B | -15% |
| 2020-12-31 | C$0.38 B | 48.28% |
| 2019-12-31 | C$0.26 B | 41.52% |
| 2018-12-31 | C$0.18 B | -26.38% |
| 2017-12-31 | C$0.25 B | -11.48% |
| 2016-12-31 | C$0.28 B | -3.43% |
| 2015-12-31 | C$0.29 B | 139.73% |
| 2014-12-31 | C$0.12 B | 92.11% |
| 2013-12-31 | C$63.93 M | 887.42% |
| 2012-12-31 | C$6.47 M | 305.17% |
| 2011-12-31 | C$1.59 M | |
| 2002-12-31 | C$70.84 M | -36.73% |
| 2001-12-31 | C$0.11 B | 6.42% |
| 2000-12-31 | C$0.10 B | 1135.61% |
| 1999-12-31 | C$8.51 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Ultragenyx Pharmaceutical RARE | C$0.68 B | 331.32% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | C$1.75 B | 1,009.92% | 🇺🇸 USA |
 Pfizer PFE | C$23.84 B | 15,005.60% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | C$11.49 B | 7,183.59% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | C$0.34 B | 118.59% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | C$0.26 B | 69.97% | 🇺🇸 USA |